Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy.

Abstract

Retinal vessel calibre metrics were evaluated at baseline and 2 years in a FIELD substudy (n = 208). Central retinal venule calibre was significantly reduced by fenofibrate and unchanged by placebo. Arteriole metrics did not change. Larger studies relating retinal vessel calibre to future diabetes complications and response to therapy are merited.

• Authors: Nicola Quinn, Andrzej S Januszewski, Laima Brazionis, Rachel O'Connell, Nanda Aryal, Justin O'Day, Russell Scott, Paul Mitchell, Alicia J Jenkins, Anthony C Keech, FIELD Trial Study Group
• Journal: Internal medicine journal (Intern Med J) Vol. 52 Issue 4 Pg. 676-679 (04 2022) ISSN: 1445-5994 [Electronic] Australia
• PMID: 35419960 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 Royal Australasian College of Physicians.

Chemical References

• Fenofibrate

Topics

• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Diabetic Retinopathy (drug therapy, prevention & control)
• Fenofibrate (therapeutic use)
• Humans
• Retinal Vessels
• Venules